The central neurometabolic fingerprint of persistent spinal pain syndrome type 2: A prospective [¹⁸F]FDG PET/CT neuroimaging study.
4 affiliations
- 1Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Nijmegen, 6525GA, The Netherlands.
- 2Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, 6525GA, the Netherlands.
- 3Chronic Pain Department, Sint Maartenskliniek, Nijmegen, 6574NA, the Netherlands.
- 4Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, 04103, Germany.
Abstract
Persistent spinal pain syndrome type 2 (PSPS-T2) is a disabling pain condition that persists after spinal surgery. While spinal cord stimulation (SCS) offers symptomatic relief, objective biomarkers to guide diagnosis and treatment are lacking. In this prospective cohort study, fifteen PSPS-T2 patients underwent dedicated [¹⁸F]FDG PET/CT brain imaging prior to SCS implantation. Group-level metabolic patterns were compared to matched healthy controls using statistical parametric mapping. Regional metabolism was correlated with pain scores and neurotransmitter PET atlases using JuSpace. PSPS-T2 patients exhibited a distributed pattern of altered glucose metabolism involving frontal, temporal and cerebellar regions. Significant hypermetabolism was observed in the left temporal pole, right inferior temporal gyrus, and bilateral cerebellar lobule VIII, whereas hypometabolism was identified in the right fusiform gyrus, right superior frontal gyrus, left gyrus rectus, and cerebellar vermis. Moreover, there were significant spatial correlations between these metabolic changes and serotonergic and glutamatergic neurotransmitter systems. Furthermore, higher baseline pain was associated with increased frontal and temporal metabolism, whereas post-intervention pain was negatively correlated with metabolism in the temporal pole. These findings suggests that PSPS-T2 is characterized by network-level alterations in brain regions integrating sensory, emotional, and cognitive aspects of pain, with a neurochemical signature implicating serotonergic and glutamatergic systems. Although preliminary, this works provides evidence for a disease-relevant neurometabolic profile and highlights the potential of [¹⁸F]FDG PET/CT for investigating central pain mechanisms. Future research should focus on validating this marker in larger populations.
Related
- Clinical Phenotypes, Neuroimaging, and Outcomes in Prolonged and Persistent Non-Motor Migraine Aura: A Systematic Review and Episode-Level Synthesis
- Multimodal Prediction of Distressing and Persistent Psychotic-Like Experiences in Adolescence across Environment, Genetics, and Neuroimaging
- Clinical and Somatosensory Correlates of Persistent Zoster-Associated Pain at One Month: A Prospective Multicenter Cohort Study
- Stage-dependent associations of Cardiovascular-Kidney-Metabolic Syndrome with Cognitive Decline, Depression, and Neuroimaging Signatures in multi-regional older adults
- Longitudinal Visual Recovery and Exploratory Neuroimaging Findings in Pediatric Deprivation Amblyopia Following Unilateral Congenital Cataract Extraction: A Prospective Cohort Study
BibTeX
@article{burmeister2026central,
title = {{The central neurometabolic fingerprint of persistent spinal pain syndrome type 2: A prospective [¹⁸F]FDG PET/CT neuroimaging study.}},
author = {Lara S Burmeister and Max van Grinsven and Bert-Kristian van Roosendaal and Richard L Witkam and Inge Arnts and Stephanie Janssen and Jessica Wegener and Kris C P Vissers and Anne I J Arens and Martin Gotthardt and Michael Rullmann and Dylan Henssen},
journal = {Neurobiology of pain (Cambridge, Mass.)},
year = {2026},
month = jul,
doi = {10.1016/j.ynpai.2026.100235},
url = {https://europepmc.org/article/MED/42898463},
note = {CC BY},
}
RIS
TY - JOUR
TI - The central neurometabolic fingerprint of persistent spinal pain syndrome type 2: A prospective [¹⁸F]FDG PET/CT neuroimaging study.
AU - Lara S Burmeister
AU - Max van Grinsven
AU - Bert-Kristian van Roosendaal
AU - Richard L Witkam
AU - Inge Arnts
AU - Stephanie Janssen
AU - Jessica Wegener
AU - Kris C P Vissers
AU - Anne I J Arens
AU - Martin Gotthardt
AU - Michael Rullmann
AU - Dylan Henssen
PY - 2026
DA - 2026/07/01
JO - Neurobiology of pain (Cambridge, Mass.)
DO - 10.1016/j.ynpai.2026.100235
UR - https://europepmc.org/article/MED/42898463
AB - Persistent spinal pain syndrome type 2 (PSPS-T2) is a disabling pain condition that persists after spinal surgery. While spinal cord stimulation (SCS) offers symptomatic relief, objective biomarkers to guide diagnosis and treatment are lacking. In this prospective cohort study, fifteen PSPS-T2 patients underwent dedicated [¹⁸F]FDG PET/CT brain imaging prior to SCS implantation. Group-level metabolic patterns were compared to matched healthy controls using statistical parametric mapping. Regional metabolism was correlated with pain scores and neurotransmitter PET atlases using JuSpace. PSPS-T2 patients exhibited a distributed pattern of altered glucose metabolism involving frontal, temporal and cerebellar regions. Significant hypermetabolism was observed in the left temporal pole, right inferior temporal gyrus, and bilateral cerebellar lobule VIII, whereas hypometabolism was identified in the right fusiform gyrus, right superior frontal gyrus, left gyrus rectus, and cerebellar vermis. Moreover, there were significant spatial correlations between these metabolic changes and serotonergic and glutamatergic neurotransmitter systems. Furthermore, higher baseline pain was associated with increased frontal and temporal metabolism, whereas post-intervention pain was negatively correlated with metabolism in the temporal pole. These findings suggests that PSPS-T2 is characterized by network-level alterations in brain regions integrating sensory, emotional, and cognitive aspects of pain, with a neurochemical signature implicating serotonergic and glutamatergic systems. Although preliminary, this works provides evidence for a disease-relevant neurometabolic profile and highlights the potential of [¹⁸F]FDG PET/CT for investigating central pain mechanisms. Future research should focus on validating this marker in larger populations.
SN - 2452-073X
ER -